Drugs / Disperse Blue 106
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00640250 | Apr 2008 → Mar 2009 | contact dermatitis | Allerderm | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00640614 | Apr 2008 → Aug 2009 | contact dermatitis | Allerderm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Disperse Blue 106 | “Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse...” NCT00640614 ↗1“Disperse blue 106 in PVP, 0.15 mg/cm2” NCT00640250 ↗ |
| Route | Topical | “Test patches, with allergens, are placed at day one and removed 48 hours later.” NCT00640250 ↗ |